| The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. | |
| | |
MedLine Citation:
|
PMID: 21136163 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Therapies that can slow the progression of liver fibrosis in chronic liver disease are needed. Evidence suggests that the renin-angiotensin system (RAS) contributes to inflammation and fibrosis in chronic liver disease. Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties. AIMS: In this study, we evaluated the effects of continuous ACEi/ARB use for 3.5 years on histological liver fibrosis progression in the HALT-C Trial cohort. METHODS: In the HALT-C Trial, subjects with chronic hepatitis C and advanced hepatic fibrosis (Ishak stage ≥3) underwent serial liver biopsies at baseline, 1.5 years, and 3.5 years after randomization. The primary outcome was a ≥2-point increase in Ishak fibrosis score in at least one of the two serial biopsies. Sixty-six subjects were continuously taking ACEi/ARBs over the observation period, 126 were taking other antihypertensive medications, and 343 subjects took no antihypertensive medications. RESULTS: The three groups were similar in baseline fibrosis scores, and the two groups being treated with antihypertensives were taking a similar number of antihypertensive medications. Fibrosis progression occurred in 33.3% of the ACEi/ARB group, 32.5% of the other antihypertensive medications group, and in 25.7% of subjects taking no antihypertensive medications. No significant associations between ≥2-point increases in fibrosis scores and continuous ACEi/ARB use were apparent at either 1.5 or 3.5 years in diabetes-adjusted and unadjusted odds ratios. CONCLUSIONS: ACEi/ARB therapy did not retard the progression of hepatic fibrosis. |
| | |
Authors:
|
Barham K Abu Dayyeh; May Yang; Jules L Dienstag; Raymond T Chung |
Related Documents
:
|
15202443 - The turning point from an archaic arab medical system to an early modern european syste... 11423683 - Train wrecks to typhoid fever: the development of railroad medicine organizations, 1850... 814993 - Cost analysis of leukemia treatment: a problem-oriented approach. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-12-07 |
Journal Detail:
|
Title: Digestive diseases and sciences Volume: 56 ISSN: 1573-2568 ISO Abbreviation: Dig. Dis. Sci. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-28 Completed Date: 2011-03-11 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 7902782 Medline TA: Dig Dis Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 564-8 Citation Subset: AIM; IM |
Affiliation:
|
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. babudayyeh@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Angiotensin Receptor Antagonists / therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Female Hepatitis C, Chronic / complications* Humans Liver Cirrhosis / etiology, prevention & control* Male Middle Aged |
| Grant Support | |
ID/Acronym/Agency:
|
1 UL1 RR 025780-01/RR/NCRR NIH HHS; 1 UL1 RR024982-01/RR/NCRR NIH HHS; 1 UL1 RR024986/RR/NCRR NIH HHS; 1 UL1 RR025758-01/RR/NCRR NIH HHS; K24 DK078772-03/DK/NIDDK NIH HHS; K24 DK078772-05/DK/NIDDK NIH HHS; M01RR-00042/RR/NCRR NIH HHS; M01RR-00043/RR/NCRR NIH HHS; M01RR-00051/RR/NCRR NIH HHS; M01RR-00065/RR/NCRR NIH HHS; M01RR-00633/RR/NCRR NIH HHS; M01RR-00827/RR/NCRR NIH HHS; M01RR-01066/RR/NCRR NIH HHS; M01RR-06192/RR/NCRR NIH HHS; N01 DK092318/DK/NIDDK NIH HHS; N01 DK092319/DK/NIDDK NIH HHS; N01 DK092320/DK/NIDDK NIH HHS; N01 DK092321/DK/NIDDK NIH HHS; N01 DK092322/DK/NIDDK NIH HHS; N01 DK092323/DK/NIDDK NIH HHS; N01 DK092324/DK/NIDDK NIH HHS; N01 DK092325/DK/NIDDK NIH HHS; N01 DK092326/DK/NIDDK NIH HHS; N01 DK092327/DK/NIDDK NIH HHS; N01 DK092328/DK/NIDDK NIH HHS; N01-DK-9-2318/DK/NIDDK NIH HHS; N01-DK-9-2319/DK/NIDDK NIH HHS; N01-DK-9-2320/DK/NIDDK NIH HHS; N01-DK-9-2321/DK/NIDDK NIH HHS; N01-DK-9-2322/DK/NIDDK NIH HHS; N01-DK-9-2323/DK/NIDDK NIH HHS; N01-DK-9-2324/DK/NIDDK NIH HHS; N01-DK-9-2325/DK/NIDDK NIH HHS; N01-DK-9-2326/DK/NIDDK NIH HHS; N01-DK-9-2327/DK/NIDDK NIH HHS; N01-DK-9-2328/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Candida queiroziae sp. nov., a cellobiose-fermenting yeast species isolated from rotting wood in Atl...
Next Document: Sequential array cytometry: multi-parameter imaging with a single fluorescent channel.